Real World Evidence Shows OS Improvements in Older Patients With AML From 2000 to 2016
A population-based study included nearly 4000 patients diagnosed with AML from 2000 to 2016 in Denmark.
Diagnosis & Disease Information
Iron Regulatory Proteins Appear to be Critical for Neutrophil Development
Although iron regulatory proteins (IRPs) may not be essential to the proliferation of stem and progenitor cells, IRPs are vital in later hematopoiesis.
UK Survey of COVID-19 With Hemoglobinopathies, Rare Anemias
According to a UK-based survery, a large number of people with hemoglobinopathies were infected with SARS-CoV-2 but COVID-19-related death was not linked.
Dasatinib-Containing Induction Therapy Associated With High Rates of Allogeneic HSCT in Newly Diagnosed Ph+ ALL
This analysis focused on the allo-HSCT-related end points in a study of patients with newly diagnosed Ph+ ALL treated with a 2-step dasatinib-containing induction regimen.
Inotuzumab Ozogamicin Plus R-CVP for Patients With DLBCL Who Are Ineligible for R-CHOP
Inotuzumab ozogamicin instead of gemcitabine added to R-CVP did not improve OS or PFS, but less toxicity among patients with untreated DLBCL with comorbid conditions.
Ropeginterferon Appears to Improve Polycythemia Vera Symptoms
The purpose of this study was to determine if a cytoreductive agent could provide additional efficacy to treat blood hyperviscosity.
FLT3-ITD With an Insertion Site in the Beta1-Sheet Prognostic for Poor Outcomes in AML
Among adult patients with newly diagnosed AML, the presence of an FLT3-ITD mutation with an insertion site in the beta1-sheet was associated shorter survival.
NBEAL2 Variants Cause Extensive Immune Dysregulation, Granule Defects in Gray Platelet Syndrome
Aside from hemostasis defect, patients with gray platelet syndrome may also have a loss of immune homeostasis.
Hematopoietic Stem Cells Primed for Erythroid Lineage in β-Thalassemia
How might β-thalassemia, an erythropoietic disorder, affect “erythroid branching” in hematopoietic differentiation?
Addition of Isatuximab to Kd Deepens Responses and Extends PFS in R/R Multiple Myeloma
The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.
- Loading...
Loading...
Next post in EHA25 Virtual Congress
Loading... 
Loading...